



Unregistered User

If this is not your name, click here

Contact Us | Order Now | Journals | Bookstore | Register a colleague

Select a Channel

SEARCH

 

- News  Medline
- Bookstore  The Web
- Meetings & Congresses
- Complete Doctor's Guide

ADVANCED SEARCH

EXPLORE :

- All News
- All Webcasts
- All Cases
- All Meetings & Congresses
- All Medical Resources

get mail

remind me

New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus

[Warning](#) | [Privacy](#) | [Awards](#)

Favourite Journals

[Click here to choose your favourite journals](#)

Favourite Sites

[Click here to choose your favourite sites](#)

Languages

Select language



Vote Now

View Results



## RSNA: Studies Suggest Role for Brachyther Lumpectomy

By Peggy Peck  
Special to DG News

CHICAGO, IL -- November 27, 2001 -- Brachytherapy either at time of surgery or over the course of five day promoted as an option for women with early, non-inva cancer.

Dr. Martin E. Keisch of Mount Sinai Medical Center, in Beach, Florida, said that five days of treatment with a catheter device called MammoSite delivers a total dos That treatment can replace the standard six-week cou radiation therapy for women with early stage non-inva cancer.

Dr. Keisch presented the results yesterday (Nov. 26) Scientific Assembly and Annual Meeting of the Radiol Society of North America, in Chicago, Illinois.

Likewise, Dr. Euan S. Thomson said a single treatme Intrabeam, a portable electron-beam device, at time o while the patient is still under anesthesia, is as effecti standard treatment.

Dr. Keisch said the MammoSite catheter is much mor friendly than brachytherapy delivered with injections, requires not only careful placement of needles, but al complicated calculation of dosing. Referring to Mamm said, "this is so simple that I can train a monkey to im to calculate the dose."

The deflated MammoSite is surgically implanted in br remaining after the tumor has been excised and is the with saline, he said. Twice a day, a radioactive seed a guide wire is advanced through the catheter into the b

"bathes the area with radiation." Because much less tissue volume is irradiated, achieving a therapeutic dose takes less time than standard radiotherapy, Dr. Keisch said.

In his study he presented results from 28 women treated with MammoSite.

"We have had no single recurrence of breast cancer," Dr. Keisch said. Most women had the device implanted while they were under local anesthesia, although a few women requested general anesthesia.

While the device is implanted, the women have a small tube protruding from the breast, but he said this is well tolerated. He said that when the device is removed, a small scar on the skin, about 1 centimeter in diameter, remains. There were no adverse effects associated with the MammoSite device, he said.

The device can be implanted at any time following lumpectomy, up to about eight weeks, he said, after that point the excision site begins to close. He said 43 women have now been successfully treated with MammoSite.

Although the device can be implanted at time of surgery, Dr. Keisch recommends waiting for pathology "to be sure you don't have an invasive carcinoma."

Dr. Thomson said his team takes a different approach with Intrabeam "during surgery so we can avoid a second surgery." The device is also implanted into the excision site and irradiated for about 20 to 30 minutes.

In a study of 29 women who had breast-conserving surgery for lesions of 3.5 cm or smaller, 15 women were treated with Intrabeam and 14 with standard six-week radiation therapy. After 18 months "no women in either group had a recurrence," Thomson said.

"Both of these approaches reflect the growing feeling among radiation oncologists that it may be sufficient to give a lower dose rather than standard therapy," Dr. Thomson said.

Dr. Thomson, who is president and CEO of Photoelectric Corporation, of Lexington, Massachusetts—the device Intrabeam is approved by the U.S. Food and Drug Administration. He said radiation oncologists at the Cleveland Clinic and New York Medical College are using the device as an alternative treatment. They irradiate at time of surgery and they follow up with standard radiation treatment.

Dr. Keisch said the MammoSite's maker, Proxima Therapeutics Inc., of Alpharetta, Georgia, expects the FDA to approve the device early in 2001.

The manufacturers, Proxima and Photoelectron, fund clinical studies.

[E-mail this page  
to a friend or colleague!](#)

[To print,  
use this version](#)

Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at [webmaster@docguide.com](mailto:webmaster@docguide.com).

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.

[Employment opportunities](#) | [Partnering opportunities](#)